Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract A117: Modeling ATM loss of function via CRISPR-Cas9 as a predictive tool for therapeutic responses in cancer cells

Lara H. El Touny, John Connelly, Curtis Hose, Anne Monks, Dianne Newton, Luke Stockwin, Melinda Hollingshead, Ralph Parchment, James H. Doroshow, Beverly A. Teicher, Annamaria Rapisarda

Mol Cancer Ther (2018) 17 (1_Supplement): A117.

https://doi.org/10.1158/1535-7163.TARG-17-A117

Published: 01 January 2018

View article titled, Abstract A117: Modeling ATM loss of function via CRISPR-Cas9 as a predictive tool for therapeutic responses in cancer cells

Journal Articles

Abstract A116: Temozolomide-resistant MGMT/MSI double-negative cancer cells rely on ATR signaling and homologous recombination for DNA repair and survival

Lara H. El Touny, Erik Harris, Curtis Hose, John Connelly, Anne Monks, Dianne Newton, Luke Stockwin, Melinda Hollingshead, Ralph Parchment, James H. Doroshow, Beverly A. Teicher, Annamaria Rapisarda

Mol Cancer Ther (2018) 17 (1_Supplement): A116.

https://doi.org/10.1158/1535-7163.TARG-17-A116

Published: 01 January 2018

View article titled, Abstract A116: Temozolomide-resistant MGMT/MSI double-negative cancer cells rely on ATR signaling and homologous recombination for DNA repair and survival

Journal Articles

Abstract B081: Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation

William G. Herrick, Casey L. Kilpatrick, Melinda Hollingshead, James H. Doroshow, Ralph E. Parchment, Apurva K. Srivastava

Mol Cancer Ther (2018) 17 (1_Supplement): B081.

https://doi.org/10.1158/1535-7163.TARG-17-B081

Published: 01 January 2018

View article titled, Abstract B081: Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation

Journal Articles

Abstract PL08-02: NCI patient derived models repository

James H. Doroshow, Melinda Hollingshead, Yvonne Evrard, P. Mickey Williams, Vivekananda Datta, Biswajit Das, Chih-Jian Lih, Dianne Newton

Mol Cancer Ther (2015) 14 (12_Supplement_2): PL08-02.

https://doi.org/10.1158/1535-7163.TARG-15-PL08-02

Published: 01 December 2015

View article titled, Abstract PL08-02: NCI patient derived models repository

Journal Articles

Abstract C197: Fluorescent in situ hybridization confirmation of circulating alveolar soft part sarcoma cells (CTCs) isolated from peripheral blood specimens using ApoStream™ instrumentation.

Priya Balasubramanian, Lihua Wang, Shivaani Kummar, Melinda Hollingshead, Francis Owusu, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow, Robert J. Kinders

Mol Cancer Ther (2013) 12 (11_Supplement): C197.

https://doi.org/10.1158/1535-7163.TARG-13-C197

Published: 01 November 2013

View article titled, Abstract C197: Fluorescent in situ hybridization confirmation of circulating alveolar soft part sarcoma cells (CTCs) isolated from peripheral blood specimens using ApoStream™ instrumentation.

Journal Articles

DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer

Min Chen, Daniel Shabashvili, Akbar Nawab, Sherry X. Yang, Lisa M. Dyer, Kevin D. Brown, Melinda Hollingshead, Kent W. Hunter, Frederic J. Kaye, Steven N. Hochwald, Victor E. Marquez, Patricia Steeg, Maria Zajac-Kaye

Mol Cancer Ther (2012) 11 (2): 370–382.

https://doi.org/10.1158/1535-7163.MCT-11-0458

Published: 08 February 2012

View article titled, DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract A46: A novel immunoassay (ELISA) for quantitative gamma-H2AX detection and pharmacodynamic monitoring of DNA damage induced by chemotherapeutic agents and PARP inhibitors.

Jay Ji, Yiping Zhang, Robert Kinders, Christophe Redon, Stephanie Solier, Keli Agama, Yves Pommier, William Bonner, Melinda Hollingshead, Larry Rubinstein, Alice Chen, Shivaani Kummar, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow

Mol Cancer Ther (2011) 10 (11_Supplement): A46.

https://doi.org/10.1158/1535-7163.TARG-11-A46

Published: 12 November 2011

View article titled, Abstract A46: A novel immunoassay (ELISA) for quantitative gamma-H2AX detection and pharmacodynamic monitoring of DNA damage induced by chemotherapeutic agents and PARP inhibitors.

Journal Articles

Abstract C224: A novel validated quantitative pharmacodynamic topoisomerase I covalent‐complex immunoassay

Thomas D. Pfister, Sonny A. Khin, Keli Agama, Melinda Hollingshead, Dhriti Sooryakumar, Yves Pommier, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow, Robert J. Kinders

Mol Cancer Ther (2009) 8 (12_Supplement): C224.

https://doi.org/10.1158/1535-7163.TARG-09-C224

Published: 10 December 2009

View article titled, Abstract C224: A novel validated quantitative pharmacodynamic topoisomerase I covalent‐complex immunoassay

Journal Articles

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Annamaria Rapisarda, Melinda Hollingshead, Badarch Uranchimeg, Carrie A. Bonomi, Suzanne D. Borgel, John P. Carter, Bradley Gehrs, Mark Raffeld, Robert J. Kinders, Ralph Parchment, Miriam R. Anver, Robert H. Shoemaker, Giovanni Melillo

Mol Cancer Ther (2009) 8 (7): 1867–1877.

https://doi.org/10.1158/1535-7163.MCT-09-0274

Published: 14 July 2009

View article titled, Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Journal Articles

Synergistic antitumor activity of Bevacizumab in combination with HIF-1 inhibition.

Annamaria Rapisarda, Melinda Hollingshead, Mark Raffeld, Bradley Gehrs, Suzanne Borgel, John Carter, Carrie Bonomi, Robert Shoemaker, Giovanni Melillo

Mol Cancer Ther (2007) 6 (11_Supplement): B17.

Published: 01 November 2007

View article titled, Synergistic antitumor activity of Bevacizumab in combination with HIF-1 inhibition.

Journal Articles

Evidence of in vivo efficacy for the indenoisoquinolines linked with pharmacodynamic markers for γH2AX

Melinda Hollingshead, Suzanne Borgel, John Carter, Carrie Bonomi, Raymond Divelbiss, Howard Stotler, Kelly Dougherty, Nathaniel Greenberg, Gurmeet Kaur, Yves Pommier, P Monks, Ralph Parchment, Robert Kinders, Joseph Tomaszewski, James Doroshow

Mol Cancer Ther (2007) 6 (11_Supplement): C18.

Published: 01 November 2007

View article titled, Evidence of in vivo efficacy for the indenoisoquinolines linked with pharmacodynamic markers for γH2AX

Journal Articles

Phosphorylated histone H2Ax in PBMCs as a pharmacodynamic surrogate response to DNA damage by topoisomerase I inhibitors

Jay Ji, Will Yutzy, Ravithat Putvatana, Yiping Zhang, Robert Kinders, Ralph Parchment, Melinda Hollingshead, Joseph Tomaszewski, James Doroshow, Phase 0 Team and the NCI

Mol Cancer Ther (2007) 6 (11_Supplement): C49.

Published: 01 November 2007

View article titled, Phosphorylated histone H2Ax in PBMCs as a pharmacodynamic surrogate response to DNA damage by topoisomerase I inhibitors

Journal Articles

Development and validation of a quantitative assay for γH2AX in needle biopsies using topoisomerase I inhibitors

Robert Kinders, Melinda Hollingshead, Scott Lawrence, Jay Ji, Joseph Tomaszewski, James Doroshow, Ralph Parchment, Phase 0 Team and the NCI

Mol Cancer Ther (2007) 6 (11_Supplement): C50.

Published: 01 November 2007

View article titled, Development and validation of a quantitative assay for γH2AX in needle biopsies using topoisomerase I inhibitors

Journal Articles

Human tumor cell lines in vitro provide a relevant model for topotecan-induced transcriptional changes in analogous xenografts

Anne Monks, Melinda Hollingshead, Howard Stotler, Raymond Divellbiss, Curtis Hose

Mol Cancer Ther (2007) 6 (11_Supplement): A124.

Published: 01 November 2007

View article titled, Human tumor cell lines <em>in vitro</em> provide a relevant model for topotecan-induced transcriptional changes in analogous xenografts

Journal Articles

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt

Joell J. Gills, Susan Holbeck, Melinda Hollingshead, Stephen M. Hewitt, Alan P. Kozikowski, Phillip A. Dennis

Mol Cancer Ther (2006) 5 (3): 713–722.

https://doi.org/10.1158/1535-7163.MCT-05-0484

Published: 16 March 2006

View article titled, Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt

Journal Articles

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells

Andrea I. Loaiza-Pérez, Susan Kenney, Jamie Boswell, Melinda Hollingshead, Michael C. Alley, Curtis Hose, Henry P. Ciolino, Grace C. Yeh, Jane B. Trepel, David T. Vistica, Edward A. Sausville

Mol Cancer Ther (2004) 3 (6): 715–725.

https://doi.org/10.1158/1535-7163.715.3.6

Published: 21 June 2004

View article titled, Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells

Journal Articles

Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: A potential surrogate marker for patient sensitivity

Curtis D. Hose, Melinda Hollingshead, Edward A. Sausville, Anne Monks

Mol Cancer Ther (2003) 2 (12): 1265–1272.

Published: 05 January 2004

View article titled, Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: A potential surrogate marker for patient sensitivity

NARROW

Abstract A117: Modeling ATM loss of function via CRISPR-Cas9 as a predictive tool for therapeutic responses in cancer cells

Abstract A116: Temozolomide-resistant MGMT/MSI double-negative cancer cells rely on ATR signaling and homologous recombination for DNA repair and survival

Abstract B081: Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation

Abstract PL08-02: NCI patient derived models repository

Abstract C197: Fluorescent in situ hybridization confirmation of circulating alveolar soft part sarcoma cells (CTCs) isolated from peripheral blood specimens using ApoStream™ instrumentation.

DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer

Abstract A46: A novel immunoassay (ELISA) for quantitative gamma-H2AX detection and pharmacodynamic monitoring of DNA damage induced by chemotherapeutic agents and PARP inhibitors.

Abstract C224: A novel validated quantitative pharmacodynamic topoisomerase I covalent‐complex immunoassay

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Synergistic antitumor activity of Bevacizumab in combination with HIF-1 inhibition.

Evidence of in vivo efficacy for the indenoisoquinolines linked with pharmacodynamic markers for γH2AX

Phosphorylated histone H2Ax in PBMCs as a pharmacodynamic surrogate response to DNA damage by topoisomerase I inhibitors

Development and validation of a quantitative assay for γH2AX in needle biopsies using topoisomerase I inhibitors

Human tumor cell lines in vitro provide a relevant model for topotecan-induced transcriptional changes in analogous xenografts

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells

Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: A potential surrogate marker for patient sensitivity

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only